{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=32", "query": { "intervention": "Advanced therapy", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 6313, "total_pages": 632, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T00:59:41.827Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00093652", "title": "Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2003-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-06", "last_synced_at": "2026-11-15T00:59:41.827Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093652" }, { "nct_id": "NCT04188548", "title": "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Advanced Breast Cancer", "Metastatic Breast Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "LY3484356", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Alpelisib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Aromatase Inhibitor (AI)", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 379, "start_date": "2019-12-10", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-11-15T00:59:41.827Z", "location_count": 42, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Springdale, Arkansas + 31 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04188548" }, { "nct_id": "NCT03371017", "title": "A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 595, "start_date": "2018-01-11", "completion_date": "2024-10-23", "has_results": true, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-11-15T00:59:41.827Z", "location_count": 6, "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • Paramus, New Jersey + 3 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Paramus", "state": "New Jersey" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03371017" }, { "nct_id": "NCT00112489", "title": "Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 55, "start_date": "2005-05", "completion_date": null, "has_results": true, "last_update_posted_date": "2018-09-25", "last_synced_at": "2026-11-15T00:59:41.827Z", "location_count": 99, "location_summary": "Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 73 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112489" }, { "nct_id": "NCT00215982", "title": "Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2004-12", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-11-15T00:59:41.827Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00215982" }, { "nct_id": "NCT03286296", "title": "LZM009 to Treat Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Livzon Pharmaceutical Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-08-21", "completion_date": "2019-04-23", "has_results": false, "last_update_posted_date": "2019-08-02", "last_synced_at": "2026-11-15T00:59:41.827Z", "location_count": 2, "location_summary": "Grand Rapids, Michigan • San Antonio, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03286296" }, { "nct_id": "NCT00603408", "title": "Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Mastectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 5, "start_date": "2007-12", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2016-08-19", "last_synced_at": "2026-11-15T00:59:41.827Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00603408" }, { "nct_id": "NCT05256290", "title": "Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Advanced Non-Small Cell Squamous Lung Cancer", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Cancer", "NSCLC", "Advanced Lung Carcinoma", "Epidermal Growth Factor Receptor C797S", "Epidermal Growth Factor Receptor G719X", "EGF-R Positive Non-Small Cell Lung Cancer", "EGFR-TKI Resistant Mutation" ], "interventions": [ { "name": "silevertinib (BDTX-1535) monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Black Diamond Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2022-03-31", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-11-15T00:59:41.827Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05256290" }, { "nct_id": "NCT04071223", "title": "Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Renal Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma", "Collecting Duct Carcinoma", "Kidney Medullary Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Papillary Renal Cell Carcinoma", "Stage IV Renal Cell Cancer AJCC v8", "Unclassified Renal Cell Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radium Ra 223 Dichloride", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2020-07-29", "completion_date": "2027-09-24", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T00:59:41.827Z", "location_count": 47, "location_summary": "Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04071223" }, { "nct_id": "NCT05115760", "title": "Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Locally Advanced Head and Neck Carcinoma" ], "interventions": [ { "name": "Dietary Supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2022-04-05", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-11-15T00:59:41.827Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05115760" } ] }